personalized medicine...personalized medicine: a world of opportunities a conference hosted by...

Personalized Medicine:

A World of Opportunities

A Conference Hosted By

November 28-29, 2006The Conference Center

Harvard Medical SchoolBoston, Massachusetts

Conference Program

HARVARD MEDICAL SCHOOL – PARTNERS HEALTHCARECENTER FOR GENETICS AND GENOMICS

3

November 28, 2006

Dear Colleague,

It is my pleasure to welcome you to Personalized Medicine: A World of Opportunities.

This year the Harvard-Partners Center for Genetics and Genomics (HPCGG) is delighted

to collaborate with Harvard Business School to present a conference dedicated to

addressing the integration of medicine and business in facilitating personalized medicine.

I am pleased that we are collaborating with the Personalized Medicine Coalition (PMC),

which is presenting its Second Annual Award for Leadership in Personalized Medicine at

our conference.

Personalized Medicine is made possible by three recent revolutions in Genetics. The first

is the recognition that genetics plays a very important role in virtually all aspects of

human health and disease. The second is the Human Genome Project that provided the

sequence of the human and many other genomes and the tools for high throughput

biology. The third revolution is the use of new genetic/genomic knowledge that is being

gained almost every day in patient care. This transformation provides great

opportunities for pharmaceutical, diagnostics and information technology companies, as

well as healthcare providers, payors and regulatory agencies, the physicians who use

genetic knowledge, and ultimately the patients themselves. The possibilities for reducing

suffering, restoring quality of life and facilitating the delivery of healthcare are almost

boundless. This is a great time to explore this world of opportunities.

HPCGG aspires to accelerate the promise of personalized medicine by discovering and

integrating genetic knowledge into the practice of healthcare. This conference provides

the forum for continuing discussions to help us reach that goal. I would like to take this

opportunity to thank the members of our organizing committee for their hard work in

planning this conference; our speakers for their enthusiasm in sharing their thoughts and

plans; and the program’s sponsors whose support enabled today’s conference. This is

truly an exciting time for these discussions and I am delighted you have decided

to join us.

Sincerely,

Raju Kucherlapati, Ph.D.Scientific DirectorHarvard-Partners Center for Genetics and Genomics

H A R V A R D M E D I C A L S C H O O L - P A R T N E R S H E A L T H C A R E

C E N T E R F O R G E N E T I C S A N D G E N O M I C S

4

SponsorsThis conference is organized by the Harvard-Partners Center for Genetics and Genomicsand Harvard Business School in collaboration with the Personalized Medicine Coalition.

It is made possible by the generous support of our sponsors.

SIGNATURE

GOLD

SILVER Education Sponsor: Enables medical or graduate students to attend the conference free of charge.

BRONZE

CONFERENCE SPONSOR

an Applera Corporation Business

5

Raju Kucherlapati, Ph.D., ChairScientific DirectorHarvard-Partners Center for Genetics and GenomicsPaul C. Cabot Professor of GeneticsProfessor of MedicineHarvard Medical School

Edward Abrahams, Ph.D.Executive DirectorPersonalized Medicine Coalition

Mara G. AspinallPresident, Genzyme GeneticsGenzyme Corporation

Keith F. Batchelder, M.D.Chief Executive Officer and FounderGenomic Healthcare Strategies

Michael D. ConwayDirector, Pharmaceutical and Medical Products PracticeMcKinsey & Company, Inc.

William F. Crowley Jr., M.D.Director, Clinical Research ProgramMassachusetts General HospitalProfessor of MedicineHarvard Medical School

Peter DworkinVice PresidentInvestor Relations and CorporateCommunicationsApplera Corporation

Mason Freeman, M.D.Translational Medicine Head forCardiovascular and MetabolismNovartis Institutes for Biomedical ResearchAssociate Professor of MedicineHarvard Medical SchoolRichard G. Hamermesh, D.B.A.MBA Class of 1961 Professor ofManagement PracticeHarvard Business School

Regina E. Herzlinger, D.B.A.Nancy R. McPherson Professor of Business AdministrationHarvard Business School

Marcia A. KeanChief Executive OfficerFeinstein Kean Healthcare

Gitte PedersenInvestment ManagerInvest in DenmarkRoyal Danish Consulate General’s Office

Daniel K. Podolsky, M.D.Chief Academic OfficerPartners HealthCare System, Inc.Mallinckrodt Professor of MedicineHarvard Medical School

Hakan Sakul, Ph.D.Senior DirectorLead, Infectious Disease Therapeutic AreaLead, Molecular DiagnosticsGlobal Molecular ProfilingPfizer Global Research & Development

Christine Seidman, M.D.Investigator, Howard Hughes Medical InstituteThomas W. Smith Professor of Medicine and GeneticsHarvard Medical SchoolDirector, Cardiovascular Genetics CenterBrigham and Women’s Hospital

Conference Organizing Committee

Harvard-Partners Center forGenetics and GenomicsLabs at 65 LandsdowneStreet, Cambridge

Trung DoExecutive Director,Business Development,Research Ventures & LicensingPartners HealthCare System, Inc.

Carol A. MitchellChief Administrative OfficerHarvard-Partners Center for Genetics andGenomics

Rebecca RehmEducational CoordinatorHarvard-Partners Center for Genetics andGenomics

Conference Planning Committee



6

Conference Program

Tuesday, November 28, 2006

Morning Session - Amphitheater

TIME TOPIC SPEAKER / MODERATOR

7:30 – 8:15 Registration& Continental Breakfast

8:15 Welcome Raju Kucherlapati, Ph.D.Harvard-Partners Center for Genetic and GenomicsHarvard Medical School

8:30 Targeted Medicine: Keynote Speaker: Tony L. WhiteWhat Progress Has Been Made? Chairman, President and Chief Executive OfficerWhat is Holding It Back? Applera Corporation

9:15 – 11:00 Session I: Moderator: Raju Kucherlapati, Ph.D.Treating Lung Cancer: Harvard-Partners Center for Genetic and GenomicsA Case for Personalized Medicine Harvard Medical School

9:15 The Impact of EGFR Mutations Bruce E. Johnson, M.D.on the Treatment of Lung Cancer Harvard Medical School

Dana Farber Cancer Institute

9:35 Personalized Medicine for Catherine Wheeler, M.D.Lung Cancer: AstraZenecaThe Iressa Story and a Pharmaceutical Perspective

9:55 Rules of Genetic Testing Mara G. Aspinallin Personalized Medicine Genzyme Corporation

10:15 Pharmacogenomics of Thomas G. Roberts Jr., M.D., MSocSciCancer Treatments Noonday Global Management, L.P.

Massachusetts General Hospital

10:35 Panel All Four Speakers

11:00 Break

11:30 The Danish Perspective on Keynote Speaker: Jytte Lyngvig, Ph.D.Personalized Medicine Chief Executive Officer

The Danish Medicines AgencyIntroduction by: Gitte PedersenRoyal Danish Consulate General’s Office

Luncheon & PMC Award Presentation - Rotunda & HIM Room

12:15 – 1:45 Luncheon & PMC Award Personalized Medicine Coalition's SecondPresentation Annual Award for Leadership in Personalized Medicine

The NHLBI’s Investment in Award Recipient: Elizabeth G. Nabel, M.D.Personalized Medicine Director

National Heart, Lung, and Blood Institute, NIH

Presentation by: Wayne A. Rosenkrans Jr., Ph.D.Personalized Medicine CoalitionAstraZeneca Pharmaceuticals

7

Afternoon Session - Amphitheater


2:00 – 4:00 Session II: Business Models for Moderator: Keith F. Batchelder, M.D.Personalized Therapy Genomic Healthcare Strategies

2:00 Personalized Medicine: Michael D. ConwayDeep Impact on the McKinsey & Company, Inc.Healthcare Landscape

2:20 Dako: A View on Patrik Dahlén, Ph.D.Pharmacodiagnostics Dako A/S

2:40 Personalized Medicine: John P. Glaser, Ph.D.The Information Technology Partners HealthCare System, Inc.Foundation at Partners HealthCare

3:00 Information Technology Jeffrey D. Millerin Healthcare Hewlett-Packard Company


4:00 Break

4:30 Personalized Medicine and Keynote Speaker: Regina E. Herzlinger, D.B.A.Consumer-Driven Healthcare Harvard Business School

Reception & Dinner - Elements Café

6:00 Reception & Dinner Welcome: Daniel K. Podolsky, M.D.Partners HealthCare System, Inc.Harvard Medical School

PMC Distinguished Service Award Award Recipient: Feinstein Kean HealthcareAccepted by: Marcia A. Kean

Presentation by: Edward Abrahams, Ph.D.Personalized Medicine Coalition

Personalized Medicine: Keynote Speaker: Ron WinslowAn Outsider’s Perspective Senior Medical Writer

The Wall Street Journal

Introduction by: Richard G. Hamermesh, D.B.A.Harvard Business School

Tuesday, November 28, 2006



8

Morning Session - Amphitheater


7:30 – 8:00 Continental Breakfast

8:00 Health Care in the Era of Keynote Speaker: Andrew C. von Eschenbach, M.D.Personalized Medicine Acting Commissioner

U.S. Food and Drug Administration

8:45 – 10:30 Session III: Personalized Moderator: Christine Seidman, M.D.Medicine: Defining the Outcomes Harvard Medical School

Brigham & Women’s Hospital

8:45 Warfarin Nomogram Samuel Z. Goldhaber, M.D.Development (GEM Clinical Trial) Harvard Medical School

Brigham and Women’s Hospital

9:05 Clinical Application of Louis M. Staudt, M.D., Ph.D.Gene Expression-Based National Cancer InstituteMolecular Diagnosis of Cancer

9:25 Consumerism and the Impact Robin Downeyto Health Benefits Aetna, Inc.

9:45 Applications of Personalized J. Russell Teagarden, R.Ph., M.A.Medicine Through Pharmacy Medco Health Solutions, IncBenefits


10:35 Break

11:00 – 1:00 Session IV: Improving Therapeutic Moderator: Hakan Sakul, Ph.D.Decision Making in Pfizer Global Research & DevelopmentInfectious Diseases

11:00 Lessons from the Beginning: Paul R. Billings, M.D., Ph.D.The Evolution of Personalized Laboratory Corporation of AmericaViral Care

11:20 Influence of Host Genetics Michael A. Zoccoli, Ph.D.on Infectious Disease Celera

11:40 Pharmaceutical/Diagnostic Chris Meda, M.S.Co-Development: Roche Molecular DiagnosticsAssessment and Process

12:00 A Diagnostic-Therapeutic Andrew SchmeltzCase Study: The Monogram-Pfizer Pfizer Global PharmaceuticalsPartnership to Advance HIV Care William J. Welch

Monogram Biosciences, Inc.

12:20 Panel All Five Speakers

12:50 Closing Comments Raju Kucherlapati, Ph.D.Harvard-Partners Center for Genetic and GenomicsHarvard Medical School

1:00 Box Lunch

Wednesday, November 29, 2006

Conference Program continued

9

Conference Speakers

Edward Abrahams, Ph.D.Edward Abrahams, Executive Director of the PersonalizedMedicine Coalition, a non-profit educational and advocacygroup representing diverse members with an interest inadvancing medical progress through the adoption of per-sonalized medicine concepts and products, brings extensiveexperience in industry, academia, and government to theposition. As former Executive Director of the PennsylvaniaBiotechnology Association, Dr. Abrahams managed allaspects of the Association, including public advocacy, med-ical relations, and educational programs, tripling its sizeand revenues in three years. He also spearheaded the suc-cessful effort that led to the Commonwealth ofPennsylvania’s investment of $200 million to commercializebiotechnology in that state.

Previously, Dr. Abrahams had been Assistant VicePresident for Federal Relations at the University ofPennsylvania, and also held a senior administrative positionat Brown University. Before becoming a university adminis-trator, Dr. Abrahams worked seven years for the UnitedStates Congress, including as a legislative assistant toSenator Lloyd Bentsen and as an economist for the JointEconomic Committee under the chairmanship ofCongressman Lee Hamilton. In addition to articles in bothpopular and professional journals, he is the author of TheLyrical left: Randolph Bourne, Alfred Stieglitz and theOrigins of Cultural Radicalism in America.

Mara G. AspinallMara Aspinall is the President of Genzyme Genetics, a lead-ing worldwide provider of testing and consultative services.Genzyme Genetics is a division of Genzyme Corporation,one of the world’s largest biotechnology firms with morethan 8,000 employees and more than $2.5 billion in rev-enue.

From its roots 20 years ago, Genzyme Genetics has estab-lished itself as one of the industry’s foremost independentdiagnostics businesses, performing more than one milliontests annually, while leading the personalized medicine,prenatal, postnatal, infertility and oncology testing markets.Genzyme Genetics has eight laboratories across the U.S.and employs the nation’s largest network of board-certifiedgenetic counselors. Genzyme Genetics has achieved recordgrowth while setting the quality standard within the diag-nostics industry. Most recently, Genzyme Genetics acquiredthe assets of IMPATH, Inc., one of the nation’s largest can-cer testing companies, making Genzyme Genetics one ofthe top commercial laboratories in the U.S.

Under Mara’s leadership, Genzyme Genetics has expand-ed its range and reach in the marketplace. The division hassuccessfully completed and integrated four acquisitions,expanded research and development programs, and initiat-

ed new programs for community outreach and education.Mara previously served as President of another Genzymedivision, Genzyme Pharmaceuticals. In her four years asPresident, she restructured the business from generic drugmanufacturing to value-added custom production. She builta new international management team that created morethan 25% annual growth.

Prior to joining Genzyme, Mara was Director of ClientServices at Hale and Dorr LLC, and was responsible for thefirm’s worldwide practice and development, strategic plan-ning and marketing. Mara started her business career atBain & Company, an international strategic consulting firm.At Bain, she specialized in developing and implementingbusiness strategies for health care product and service com-panies.

Mara combines her professional life with active involve-ment in the community. Her two most important areas offocus are:

1) The fight against cancer: Mara is an active Boardmember of the Dana Farber Cancer Institute, where she sitson the Executive Committee as well as the Trustee ScienceCommittee. She has previously served as Chairman of theBoard of the American Cancer Society, Massachusetts.During her tenure at ACS, she oversaw the process of merg-ing the Massachusetts chapter into a newly formed NewEngland American Cancer Society.

2) Expanding educational opportunities for young chil-dren: Mara co-chairs Early Education for All, an advocacycampaign to establish statewide standards for pre-schooleducation. As a trustee of The Children’s Museum, Mara ledthe Early Childhood Education task force. As a member ofthe Leadership Council of United Way, she lobbied success-fully for the home visiting program for first time youngmothers. Mara is a frequent speaker to regional andnational organizations on creating business and legislativesupport for children’s educational programs.

Her Masters of Business Administration from HarvardBusiness School was enriched with the John P. Stevens Prizefor leadership. She has served on the board of the HBSNetwork for Women. A magna cum laude graduate of TuftsUniversity, Mara majored in International Relations.

Keith F. Batchelder, M.D.At Genomic Healthcare Strategies, Keith Batchelder evalu-ates partnership and commercialization opportunities for“personalized medicine” IP, drugs and technologies alongwith their potential for success in the markets. He gainedthis experience by servicing venture capital, pharma andbiotech organizations.

Dr. Batchelder served as chief technical officer ofWorldCare International Clinical Trials, enabling drugs toreceive regulatory approval at the end of Phase II clinical

continued



10

Conference Speakers continued

trials by using surrogate endpoints. He was a core memberof Harvard Salud Integral, a new HMO in Mexico City,growing the plan to over 150,000 covered lives. As a princi-pal of AMICAS, he helped make Web based radiology (510kapproved) a viable software company (liquidity event in2002).

Dr. Batchelder was on the professional staff ofMassachusetts General Hospital for 8 years. He was educat-ed at Middlebury College, the Hahnemann UniversitySchool of Medicine, and received postgraduate training inMedical Informatics at The Boston VA Hospital.

Paul R. Billings, M.D., Ph.D.Dr. Paul Billings is Senior Vice President for CorporateDevelopment and Strategy at Laboratory Corporation ofAmerica Holdings (LabCorp) and Senior Geneticist atLabCorp’s Center for Molecular Biology and Pathology. Hehad been Vice President and National Director of Geneticsand Genomics previously. LabCorp with over $3 billion inannual revenue and 24 thousand employees is one of thelargest providers of genetic and genomic tests in the world,developing and applying new technologies to support thehighest quality research and health care. He is also a Co-Founder of GeneSage, Inc. where he recently acted asExecutive Vice President and Chief Scientific and MedicalOfficer. GeneSage is a new company that seeks to trans-late the promise of progress in human genetics in to solu-tions for health care providers and consumers. He has beenEditor-in-Chief of GeneSage’s GeneLetter, the leading on-line magazine of genetic medicine, society and culture. Inaddition, Dr. Billings is a Professor in the Department ofAnthropology at the University of California at Berkeley(Adjunct) and is past Principal Investigator on a RobertWood Johnson Foundation funded projects studying theimpact of genomic medicine on health care. Prior to joiningLabCorp, Dr. Billings was Vice President for Life Sciencesand Clinical Affairs at WIPRO, Ltd., via its subsidiary WIPROHealthScience. WIPRO, based in India, is a leading globalprovider of consultative products and services to improvethe efficiency and quality of health care. Dr. Billings hasbeen a member of the faculties at Harvard Medical School,the University of California at San Francisco, StanfordUniversity and the University of California at Berkeley. Hehas also served as Chief of the Division of Genetic Medicineand Vice-Chairman of the Department of Medicine at PacificPresbyterian Medical Center in San Francisco (now calledthe California Pacific Medical Center) where he founded theCenter for Inherited Diseases and led the Program inGenetics and Society, the Center for Adults with CysticFibrosis, the Breast Cancer Risk Assessment andManagement Program, as well as the Prenatal DiagnosticCenter at Alta Bates Hospital.

Dr. Billings received his MD and PhD degrees from

Harvard University in 1979. He completed his clinical train-ing in Internal Medicine and Medical Genetics at theUniversity of Washington in Seattle in 1983. He is aFounding Fellow of the American College of MedicalGenetics, a Fellow of the American College of Physiciansand a past Distinguished Lecturer for the national sciencesociety, Sigma Xi. He chairs the Medical Advisory Board ofCord Blood Registry, Inc. where he previously was MedicalDirector, and has been Board Chairman of the Alpha-1Association and the Council for Responsible Genetics. He isalso a member of the Board of Directors of the Cord BloodDonor Foundation and the Cardiac Arrhythmia Researchand Education Foundation.

Michael D. ConwayMichael Conway is a Director in McKinsey’s Philadelphiaoffice. Since joining McKinsey in late 1993, Michael has pri-marily worked in the pharmaceutical, biotechnology, privateequity, and public health arenas. Michael is currently theleader of McKinsey Global Public Health Sub-sector, and heleads Advance Professional Degree Recruiting (MD, PhD,and JD). The main focus of his client work is on productlicensing, corporate strategy, product strategies, operationsimprovements, and organizational design.

Michael is the co-leader of McKinsey’s knowledge initia-tive in Personalized Medicine. Michael has worked withseveral major pharmaceutical companies on personalizedmedicine-related partnering strategies and elements ofproduct strategies. Michael has also participated in a broadrange of discussions on personalized medicine topics withacademic medical centers, pharmaceutical companies andpayors.

Michael holds a B.S. in biochemistry from Texas A&MUniversity and a J.D. from the University of Chicago LawSchool.

Patrik Dahlén, Ph.D.Patrik Dahlén has been the President and Chief ExecutiveOfficer of Dako A/S since 2005. Dako is one of the world’sleading companies in cancer diagnostics, devoted to help-ing pathologists improve their ability to diagnose cancer.To this end, Dako develops, manufactures and markets cell-based cancer diagnostics for both clinical diagnostics andresearch use. Dako is headquartered in Denmark with man-ufacturing and research sites in Glostrup, Denmark, FortCollins, Colorado and Carpinteria, California. Previously, Mr.Dahlén was the CEO of BioImage A/S, President ofPerkinElmer Life Sciences, Inc., General Manager at bothEG&G Reticon, Inc. and Wallac Isolab, Inc. He has been amember of the boards at DakoCytomation A/S, Proxeon A/Sand Cantion A/S. Mr. Dahlén received his M.Sc. in biochem-istry from Åbo Akademi University, Turku and his Ph.D. inbiochemistry from University of Turku.

11

Robin DowneyRobin Downey is Senior Vice President of ProductDevelopment for Aetna, one of the nation’s leading healthbenefits organizations. In her role, she is responsible forcreating the evolution of the company’s portfolio of healthbenefits which includes a broad array of consumer-directedproducts, performance networks, HMO, PPO, POS, andindemnity products. She works closely with leaders fromthroughout the Aetna organization, as well as Aetna cus-tomers and industry consultants, to ensure that the compa-ny’s product offerings meet ever-changing constituentneeds.

Downey continues to help the company remain in theforefront of health care consumerism through a variety ofindustry firsts. These include the first fully insured offeringfor middle market employers, and the first fully integratedand stand-alone pharmacy and dental products. Aetna alsowas the first health benefits company to publicly announcean HSA offering in December of 2003. Downey’s team alsois responsible for developing the Aetna Navigator suite ofconsumer tools and information. In August 2005, Aetnacontinued its leadership position in the category as the firsthealth benefits company to provide its members withonline access to the actual discounted rates for the mostcommon office-based procedures provided by primary careand specialist physicians.

John P. Glaser, Ph.D.John Glaser, PhD, is Vice-President and Chief InformationOfficer, Partners HealthCare System, Inc. Previously, he wasVice-President, Information Systems at Brigham andWomen’s Hospital. Prior to Brigham and Women’s Hospital,Dr. Glaser managed the Healthcare Information Systemsconsulting practice at Arthur D. Little. Dr. Glaser was thefounding Chairman of College of Healthcare InformationManagement Executives (CHIME) and is past President ofthe Healthcare Information and Management SystemsSociety (HIMSS). He has been a member of the Board of theAmerican Medical Informatics Association. Dr. Glaser is cur-rently the Chairman of the eHealth Initiative Board and theSenior Advisor for National HIT Adoption for CHIME. He is aSenior Advisor to the Deloitte Center for Health Solutions.

He is a fellow of HIMSS, CHIME and the AmericanCollege of Medical Informatics. He has been awarded theJohn Gall award for healthcare CIO of the year. CHIME hasestablished a scholarship in Dr. Glaser’s name. He was arecipient of CIO Magazine’s 20/20 Vision Award. PartnersHealthCare has received several industry awards for itseffective and innovative use of information technology. Dr.Glaser has published over one hundred articles and fourbooks on the strategic application of information technolo-gy in healthcare.

He holds a Ph.D. in Healthcare Information Systems fromthe University of Minnesota.

Samuel Z. Goldhaber, M.D.Samuel Z. Goldhaber, MD, Professor of Medicine at HarvardMedical School and Staff Cardiologist at Brigham andWomen’s Hospital (BWH), is Director of the BWH VenousThromboembolism Research Group. As Founder andDirector of the BWH Anticoagulation Service, which caresfor more than 1,900 active patients, he conducts researchon optimal effective and safe warfarin anticoagulation,pharmacogenomics, and novel anticoagulant agents. He isan active clinician, attending on the Cardiology Services ofBrigham and Women’s Hospital and evaluating outpatientswith cardiovascular and thrombotic illnesses. Dr. Goldhaberco-directs three Harvard Medical School Continuing MedicalEducation courses: 1) a 5-day course reviewing all aspectsof cardiovascular medicine, 2) a 2-day course reviewingthrombosis and thromboembolism, and 3) a 1-day coursethat focuses on venous thromboembolism prophylaxis. Onbehalf of the North American Thrombosis Forum, Dr.Goldhaber is also organizing a February 17, 2007Thrombosis Summit meeting in Boston.

Richard G. Hamermesh, D.B.A.Richard Hamermesh is the MBA Class of 1961 Professor ofManagement Practice at the Harvard Business Schoolwhere he teaches in the MBA Program and is the FacultyChair of the HBS Healthcare Initiative. Richard created andteaches the second-year MBA elective, Entrepreneurshipand Venture Capital in Healthcare. Previously, he was theCourse Head for the required first year course entitled TheEntrepreneurial Manager.

From 1987 to 2001, Richard was a co-founder and aManaging Partner of The Center for Executive Development,an executive education and development consulting firm.Prior to this, from 1976 to 1987, he was a member of thefaculty of the Harvard Business School.

Richard is also an active investor and entrepreneur, hav-ing participated as a principal, director, and investor in thefounding and early stages of over 20 organizations. Thesehave included start-ups, leveraged buy-outs, industry roll-ups, and non-profit foundations. He was the founding presi-dent of the Newton (MA) Schools Foundation and servedon the editorial board of the Harvard Business Review. He iscurrently on the Boards of one public and two private cor-porations, as well as two non-profit Boards. From 1991 to1996, he was the founding Chairman of Synthes Spine, Inc.Richard’s best-known book, Fad-Free Management, waspublished in 1996. Richard received his BA from theUniversity of California, and his MBA and DBA from HBS.He is married, has two children, and his hobbies includetennis, skiing, and yoga.

continued



12


Regina E. Herzlinger, D.B.A.Regina E. Herzlinger is the Nancy R. McPherson Professor ofBusiness Administration Chair at the Harvard BusinessSchool. She was the first woman to be tenured and chairedat Harvard Business School and the first to serve on a num-ber of corporate boards. She is widely recognized for herinnovative research in health care, including her early pre-dictions of the unraveling of managed care and the rise ofconsumer-driven health care and health care focused facto-ries, two terms that she coined. Money has dubbed her the“Godmother” of consumer-driven health care. ReginaHerzlinger received her Bachelor’s Degree from MIT and herDoctorate from the Harvard Business School.

Her research has been profiled in numerous industry jour-nals and business publications, such as The Economist andBusinessWeek. Her newest book, Consumer-Driven HealthCare: Implications for Providers, Payers, and Policymakers(San Francisco: Jossey-Bass, 2004), was profiled in “Are youready to own your health care?” Money, November 2004,and received the 2004 American Journal of Nursing Book ofthe Year award for History and Public Policy. Earlier researchresults were profiled by The Wall Street Journal (November2002), Managed Health Care Executive (June 2003, cover).Her July 2002 Harvard Business Review article, “Let’s PutConsumers in Charge of Health Care,” was an Amazonebooks best seller. She has also won the American Collegeof Healthcare Executives’ Hamilton Book of the Year awardtwice, the Healthcare Financial Management Association’sBoard of Directors award, and Management Accounting’sresearch prize. Modern Healthcare readers selected her asone of 2003’s, 2004’s and 2005’s “100 Most PowerfulPeople in Healthcare” and Managed Healthcare named heras one of health care’s top ten thinkers. In recognition ofher work in nonprofit accounting and control, she wasnamed the first Chartered Institute of ManagementAccountants Visiting Professor at the University ofEdinburgh. In addition, she has delivered many keynoteaddresses at annual meetings of large health care and busi-ness groups and been selected as one of the outstandinginstructors of the Harvard Business School MBA Program.

Mrs. Herzlinger has served on the Scientific AdvisoryGroup to the U.S. Secretary of the Air Force and as a boardmember of many publicly-traded firms, often as chair ofseveral Governance and Audit subcommittees. She is alsoan active participant in the HBS Healthcare Initiative.

Bruce E. Johnson, M.D.Bruce E. Johnson, MD is Director of the Carole M. and PhilipL. Lowe Thoracic Oncology Program at the Dana-FarberCancer Institute (DFCI). He is also Director of the Dana-Farber/Brigham and Women’s Thoracic Oncology Programand leads the Dana-Farber/Harvard Cancer Center LungCancer Program that includes the seven Harvard MedicalSchool affiliated institutions.

Dr. Johnson is the principal investigator of the Dana-Farber/Harvard Cancer Center Specialized Program ofResearch Excellence (SPORE) in Lung Cancer, and holds theposition of Associate Professor of Medicine at the Brighamand Women’s Hospital and Harvard Medical School.

His laboratory-based research is devoted to testing noveltherapeutic agents for their efficacy against lung cancerand other thoracic malignancies. His group helped discoverthat patients with partial and complete responses to specif-ic epidermal growth factor receptor (EGFR) inhibitors havemutations in the receptor. Dr. Johnson leads a researchteam that is applying these findings to the clinical treat-ment of patients with lung cancer.

Dr. Johnson is active in various organizations at thenational and international level. He is currently chair of thebiology subcommittee of the external scientific committeefor the National Cancer Institute’s National Human GenomeResearch Institute Pilot Project Characterizing CancerGenomes and was the chair for the National CancerInstitute’s review committee on Early Detection ResearchNetwork: Biomarkers Development Laboratory. He served aschair of the American Society of Clinical OncologyCommunications Committee for the last three years, andbecame chair of the Education Committee in July 2007. Heis Chair of the Committee that drafts the National CancerCenter Network Guidelines on the treatment of small celllung cancer and recently received the Tisch FamilyOutstanding Achievement Award in Translational andClinical Research in Solid Tumors from the Dana-FarberCancer Institute.

Dr. Johnson has authored over 135 original reports inpeer-reviewed journals and more than 80 reviews, chaptersand editorials. He serves on the editorial board of ClinicalCancer Research, International Journal of Oncology andJournal of Clinical Oncology.

Dr. Johnson earned his undergraduate degree at HarvardCollege and received his medical degree from the Universityof Minnesota in 1979. He completed his postgraduate train-ing at the University of Chicago and the National CancerInstitute (NCI). He joined The Dana-Farber Cancer Institutein 1999, after serving at NCI as the head of the LungCancer Biology Section.

Marcia A. KeanMarcia Kean was appointed Chief Executive Officer ofFeinstein Kean Healthcare (FKH) in December 2002. She hasclose to 30 years of health care industry experience, includ-ing senior positions with pharmaceutical, biotechnologyand medical service firms and non-profit research organiza-tions.

In 2003, Mrs. Kean initiated at FKH the first MolecularMedicine communications practice in the country. TheMolecular Medicine Practice provides communication coun-sel and services to companies and related policy organiza-

13

tions focused on new technologies, products, policies andissues in the emerging field of genomic-based medicine andhealth. Among the clients of FKH’s Molecular Medicinepractice are the National Cancer Institute, the PersonalizedMedicine Coalition, Harvard Medical School-PartnersHealthcare Center for Genetics and Genomics (HPCGG),University of California at San Francisco, Baylor College ofMedicine, Monogram Biosciences, and the PharmaceuticalResearch and Manufacturers of America (PhRMA). Mrs.Kean is a member of the Genetics Advisory Council ofHPCGG, and serves as an advisor to the Board of thePersonalized Medicine Coalition. She holds an MBA inFinance from New York University and a B.A. from theUniversity of California at Berkeley.

Jytte Lyngvig, Ph.D.Jytte Lyngvig has been the Chief Executive Officer of theDanish Medicines Agency since 2000. Previously, she wasthe Director of the public market segment and internationalassignments at Mercuri Urval A/S. Before that, Dr. Lyngvigwas the Development and Marketing Director in HT atCopenhagen Transport. She also worked as both aTechnical/Administrative Official and Consultant in docu-mentation structure in the Ministry of Environment inDenmark.

Dr. Lyngvig has been a member of the E.M.E.AManagement Board since 2000, and has been Vice-Chair ofthe Board since 2003. She is also a member of the follow-ing professional bodies: IDA – The Society for DanishEngineers; Heads of Medicines Agencies ManagementGroup, Chair; Advisory Board for TOPRA (The Organizationfor Professional in Regulatory Affairs); Advisory Board forInformatics and Mathematical Modelling (Institute ofTechnical University of Denmark); Advisory Board for theDanish Agency for Governmental Management.

Dr. Lyngvig graduated in chemical engineering from theTechnical University of Denmark, where she went on tocomplete her doctorate degree in socio-economic planning.

Chris Meda, M.S.Christine A. Meda is currently the VP, Business Developmentat Roche Molecular Systems, a Business Area of Hoffman-LaRoche. Chris joined Roche Molecular at the end of 2002as VP, of the worldwide Women’s Health Business Segment.In that role, she was responsible for the strategic directionof the Women’s Health portfolio. This responsibility oversawfunding for research/development/sales and marketing/busi-ness development/operational activities and included thelaunches of real-time PCR diagnostic products forChlamydia, Human Papillomavirus (HPV), Herpes Simplexvirus and Strep B. Prior to joining Roche, Chris held severalpositions at Schering AG pharmaceuticals. First, as Directorof the CNS portfolio which included all life cycle and mar-

keting activities for Betaseron, a multiple sclerosis treat-ment and then as Medical Affairs Director responsible forPhase I, II and IV clinical trials for their hematologicaloncology drugs: Fludara, CamPath and Leukine. In the lattercapacity, her responsibilities extended to the oversight ofseveral clinical research organizations and to the co-chairof the investigator sponsor studies committee.

The remainder of Chris’ nineteen years in the healthcareindustry is comprised of executive positions at Bio-RadLaboratories where she managed the research and develop-ment/global marketing/global technical support groups forthe immunoassay reagent and CODA microtiter plate sys-tem portfolio as Business Unit Manager; MeridianDiagnostics as VP of Global Marketing for their worldwidemarkets and Diagnostic Products Corporation where sheheld numerous positions in sales and marketing includingSenior Director of Global Sales and Marketing of the infec-tious disease and allergy reagent and systems portfolio.Christine has a B.S. degree from State University of NewYork, Potsdam Campus and has completed numerous exec-utive development programs at Schering AG and Roche. Shecurrently lives with her husband and two children in WalnutCreek, CA.

Jeffrey D. MillerJeff Miller is Vice President of Worldwide Health and LifeSciences Industries and is responsible for driving health, lifesciences, and pharmaceutical industry marketing, partnerand alliance, business planning and solutions developmentstrategies, and overseeing sales activities.

Miller and his team are responsible for developing tech-nology solutions that increase access to vital informationand improve patient care by integrating devices, systems,people & organizations to gain new decision-enablinginsights and to increase business agility. Miller also isactively involved with government and industry leaders andorganizations worldwide to increase the adoption and useof technology in the health and life sciences industry.

Miller joined HP in July 2004, bringing more than twentyyears of professional experience in strategic planning, prod-uct development and operational process improvement fororganizations in the healthcare, manufacturing and technol-ogy industries. Before joining HP, Miller was ExecutiveDirector at the Advisory Board Company, where he led thedevelopment and delivery of management consulting serv-ices for hospitals and health systems. Prior to this, Millerwas a Partner in Health and Life Sciences at DeloitteConsulting, where he led the sales and delivery of a diverseset of consulting engagements for health care providersand life sciences clients, including Kaiser Permanente,Johnson & Johnson, Cardinal Health and Pfizer. He also col-laborated with Hospitals and Health Networks magazine tocreate the Most Wired Hospitals and Health Systems pro-gram which focuses on identifying the role of informationtechnology in connecting the different members of the

continued



14

health ecosystem. Previously, he was a Program Director atIBM, where he managed a variety of business strategy,product planning, and development organizations, andintroduced HealthVillage, an Internet Application for health-care providers and payors.

Miller holds an MBA from the Fuqua School of Businessat Duke University in Durham, North Carolina and a BA inEconomics from Northwestern University in Chicago. He isbased in Research Triangle Park, North Carolina.

Elizabeth G. Nabel, M.D.Dr. Elizabeth G. Nabel, a native of St. Paul, Minnesota,received her M.D. degree from Cornell University MedicalCollege in 1981. She then completed an internship and resi-dency in internal medicine followed by a clinical andresearch fellowship in cardiovascular medicine at Brighamand Women’s Hospital, Harvard University. In 1987, shejoined the faculty at the University of Michigan as anAssistant Professor of Medicine and rose through the ranks,becoming Director of the Cardiovascular Research Center in1992, Professor of Medicine and Physiology in 1994, andChief of the Division of Cardiology in 1997. A cardiologistwith extensive clinical experience, Dr. Nabel has had a dis-tinguished career as a researcher. While at the University ofMichigan, she became known for her research in the fieldsof vascular biology and molecular cardiology and for hergene transfer studies of the cardiovascular system.

Dr. Nabel joined the National Heart, Lung, and BloodInstitute (NHLBI) in 1999 as the Institute’s ScientificDirector of Clinical Research. In 2005, Dr. Nabel becameDirector of the NHLBI, where she oversees an extensivenational research portfolio of basic and clinical research toprevent, diagnose, and treat heart, lung, and blood dis-eases. The Institute also conducts educational activities forhealth professionals, patients, and the general public. TheNHLBI budget for fiscal year 2006 is approximately $3.0 bil-lion, and she is responsible for approximately 850 Federalemployees.

Dr. Nabel has made many contributions to basic and clin-ical research on the pathogenesis and treatment of cardio-vascular diseases. She has long championed the concept“from bench to bedside” which is reflected in her work thatintertwines basic research and translation to clinical medi-cine. Early in her career, she made seminal discoveriesregarding genetic therapies for cardiovascular disease, hav-ing developed methods for the introduction and expressionof recombinant genes into blood vessels. These basic stud-ies were instrumental in designing device therapies, in com-bination with genes or drugs, to treat the vascular diseaserestenosis. In addition, Dr. Nabel has delineated the mecha-nisms by which cell cycle and growth factor proteins regu-late the proliferation of vascular cells in blood vessels, aprocess important for the development of atherosclerosis

and restenosis. Her vascular biology laboratory has charac-terized the role of cell cycle inhibitors on vascular prolifera-tion and inflammation, and this research has opened upnew avenues for therapeutic targets in the vasculature. Dr.Nabel’s current research focuses on the molecular geneticsof vascular diseases. She is conducting clinical studies tounderstand the contribution of genetic factors to prolifera-tive and inflammatory diseases in blood vessels, includingcommon diseases like atherosclerosis and the rare, prema-ture aging syndrome, Hutchinson Gilford ProgeriaSyndrome.

Dr. Nabel has served as a Visiting Professor at majormedical centers throughout the country. She has deliveredmajor lectureships in Europe and Australia. Dr. Nabel hasreceived numerous awards for her scientific accomplish-ments, including the Willem Einthoven Award from LeidenUniversity in the Netherlands, the Amgen-ScientificAchievement Award from the American Society forBiochemistry and Molecular Biology, and DistinguishedAchievement Awards from boththe Basic CardiovascularSciences Council and the Atherosclerosis, Thrombosis andVascular Biology Council of the American Heart Association.In 2001, she received an honorary doctorate degree fromthe University of Leuven, Leuven, Belgium, and in 2006, anhonorary degree from Mount Sinai School of Medicine inNew York City.

Dr. Nabel is an elected member of the Institute ofMedicine of the National Academy of Sciences, theAmerican Society of Clinical Investigation, and theAssociation of American Physicians, as well as a Fellow ofthe American Heart Association and the American Collegeof Cardiology. She serves on the editorial board of manyscientific journals, including being a member of the editorialboard of the New England Journal of Medicine, and pastBoard of Reviewing Editors for Science and associate editorfor the Journal of Clinical Investigation. A partner on 13patents, Dr. Nabel is the author of more than 200 scientificpublications, and she has mentored more than 45 studentsand fellows.

Gitte PedersenGitte Pedersen works as Investment Manager in Invest inDenmark. Invest in Denmark is a governmental agency, anda part of the foreign ministry of Denmark. Invest inDenmark facilitates expansion of US companies to Denmarke.g. Invest in Denmark played a pivotal role in Biogen’sdecision to establish a manufacturing plant in Copenhagen– a $350 mill investment. Gitte is heading up the biotechinitiative in North America.

Previously Gitte worked for Novo Nordisk in a number ofmanagement positions within R&D and Marketing. NovoNordisk is one of the largest Biotech Companies in theworld and the market leader within areas such as industrial


15

enzymes and insulin for treatment of diabetes. GittePedersen co-authored 8 patents while working in R&D.

In 2000, Gitte Pedersen co-founded Genomic Expression,a company in Denmark and went to the finals in VentureCup, a business plan competition arranged by McKinsey, forthe best business plan in the Scandinavian region.

Gitte graduated from the Danish Technological Universitywith top scores in Biochemical Engineering and she holds abachelor’s degree in International Trade.

Daniel K. Podolsky, M.D.Dr. Daniel K. Podolsky serves as Chief Academic Officer ofPartners HealthCare System and Faculty Dean of HarvardMedical School for Academic Programs at Partners. Dr.Podolsky also serves as the Mallinckrodt Professor ofMedicine at Harvard Medical School and since 1989 asChief of Gastroenterology of Massachusetts GeneralHospital. He received his undergraduate degree fromHarvard College and his medical degree from HarvardMedical School, followed by residency training in InternalMedicine and a fellowship at Massachusetts GeneralHospital.

Dr. Podolsky is an authority on inflammatory bowel dis-eases and other digestive disorders. His research interestshave focused on the delineation of epithelial cell function,and his laboratory has made significant contributions tounderstanding the mechanisms through which growth fac-tors and cytokines regulate epithelial function and themechanisms of epithelial injury and repair. He is the authorof more than three hundred original research and reviewarticles, the past editor-in-chief of the journalGastroenterology and has been actively involved in numer-ous national organizations, including serving as President ofthe American Gastroenterological Association in 2003-04.

Thomas G. Roberts Jr., M.D., MSocSciDr. Roberts joined Noonday in 2005 as a portfolio manager.Prior to joining Noonday, Dr. Roberts was an attendingoncologist at Massachusetts General Hospital, an Instructorof Medicine at the Harvard Medical School, and a VisitingScientist at Massachusetts Institute of Technology. He alsoholds appointments at the MGH Institute of TechnologyAssessment and the MIT Program on the PharmaceuticalIndustry. He is board certified in Internal Medicine andMedical Oncology.

Dr. Roberts obtained two baccalaureate degrees (SummaCum Laude) from the University of Pennsylvania, includinga Bachelors of Science from the Wharton School ofBusiness. He obtained his medical degree from HarvardMedical School (Commencement speaker). Dr. Roberts per-formed his internal medicine training at the MassachusettsGeneral Hospital and his medical oncology training through

the Dana-Farber/Partners Cancer Care Oncology FellowshipProgram. He has spoken widely and has published exten-sively on issues surrounding cancer drug development andpharmacoeconomics.

Wayne A. Rosenkrans Jr., Ph.D.Dr. Rosenkrans is currently Business Strategy Director forExternal Scientific Affairs at AstraZeneca Pharmaceuticals.In that role he has responsibility for long-range strategydevelopment supporting AstraZeneca’s external scientificinfluencing policy through US Regulatory Affairs and USMedical Affairs. He is a recipient of the Society ofCompetitive Intelligence Professionals (SCIP) FellowsAward, and a former President of the Society. Previous posi-tions include Global Director, Intelligence Affairs atAstraZeneca, Director – US Intelligence at AstraZeneca,Competitive Technical Intelligence Group Leader andResearch Planning Analyst at Zeneca Pharmaceuticals,Director of Strategic Intelligence Systems for WindhoverInformation, Director of Drug Intelligence Systems Sales andMarketing for Adis International, and Associate Director andHead of Strategic Intelligence for SmithKline BeechamPharmaceuticals R&D. He has presented at various forumson aspects of strategy development, strategic early warn-ing, and strategic intelligence. He holds an S.B. in Biologyfrom MIT, a Ph.D. in Cell and Molecular Biology fromBoston Univ., and received post-doctoral training in Cancerand Radiation Biology at the Univ. of Rochester. Other inter-est areas include martial arts (Tang Soo Do) and antiqueFords (Model T, Model A, Fordson Tractor).

Hakan Sakul, Ph.D.Dr. Sakul is currently a Senior Director in Molecular Profilinggroup within the Clinical R&D at Pfizer’s GrotonLaboratories where he is leading the Molecular Profilingefforts in Infectious Diseases. Additionally, he serves as theMolecular Diagnostics program lead in the same group.

Dr. Sakul is a native of Turkey where he completed his BSand MS degrees. Then he received a Rotary scholarship topursue a Ph.D. degree in Quantitative Genetics at theUniversity of Minnesota. Upon completion of his Ph.D., hepursued his postdoctoral studies at the University ofCalifornia, Davis in quantitative genetics, animal geneticsand international agriculture, followed by a short stint withthe USDA as a Research Geneticist. Subsequently, Dr. Sakulmoved to Sequana Therapeutics, a biotechnology companybased in La Jolla, CA, where he led a Statistical Geneticsgroup in linkage and association analyses of human genet-ics data to uncover genes predisposing to common andcomplex diseases. After his tenure at SequanaTherapeutics, Dr. Sakul held the position of Director ofStatistical Genetics, Human Genetics and Pharmacogenetics

continued



16

programs with Parke-Davis Pharmaceuticals in Alameda, CAwhere he built a group to provide genetics expertise to var-ious Parke-Davis research sites. Due to site closure shortlyafter Pfizer’s acquisition of Warner-Lambert, Dr. Sakulmoved to Ardais Corporation in Lexington, MA as VicePresident of Statistical Genomics, after which he returnedto Pfizer to assume his current position.

Dr. Sakul has authored and co-authored over 30 refereedarticles. He is also the author of several book chapters,numerous abstracts and presentations. He has served as adhoc reviewer for several scientific journals, and served onvarious grant review committees. Currently, Dr. Sakul repre-sents Pfizer on the Clinical Science and TechnologyCommittee of the Personalized Medicine Coalition, and thePharmacogenetics Working Group. Dr. Sakul is keenly inter-ested in applications of pharmacogenomics and other–omics to programs in discovery, clinical development, andthrough post-marketing, and their applications in individu-alizing patient care.

Andrew SchmeltzAndrew Schmeltz is a Senior Director, Team Leader ofWorldwide Virology, where he is responsible for overseeingPfizer’s commercial strategy development and executionacross HIV/AIDS, HCV and other viral diseases. He worksclosely with discovery research and clinical developmentcolleagues to identify target compounds and to prioritizeresources to address unmet patient needs.

Andy joined Pfizer in 2003 as a Director, Team Leader forWorldwide HIV/AIDS Marketing, where he developed strate-gy to build Pfizer’s global HIV/AIDS portfolio. In that role, heled Pfizer’s efforts related to launch preparation activitiesfor the Company’s HIV portfolio, such as advocacy develop-ment, medical education and publication planning.Prior to joining Pfizer, Andy spent seven years at AbbottLaboratories in a variety of senior positions. As a marketingdirector, he led the U.S. marketing launch for Humira, anovel biological treatment for rheumatoid arthritis andother autoimmune diseases. Those efforts won him the2002 President’s & Chairman’s Award for his outstandingperformance and leadership. Similarly, he led the planningand implementation of U.S. marketing strategies for twoantiretroviral agents, Kaletra and Norvir.

Andy is a graduate of Columbia University, where hemajored in economics, as well as a graduate of theUniversity of Chicago’s Graduate School of Business, wherehe earned an MBA.

Christine Seidman, M.D.Christine (Kricket) Seidman is a Professor in theDepartments of Medicine and Genetics at Harvard MedicalSchool and Brigham and Women’s Hospital. She wasrecently named the Thomas A. Smith Professor of Medicine.

She is also an Investigator of the Howard Hughes MedicalInstitute. She was an undergraduate at Harvard Collegeand received a M.D. from George Washington UniversitySchool of Medicine in 1978. Dr. Seidman served as anintern and resident in Internal Medicine at John HopkinsHospital and received subspecialty training in cardiology atthe Massachusetts General Hospital. She joined the staff atBrigham and Women’s Hospital in 1987 and is currently theDirector of the Cardiovascular Genetics Center.

Honors include: Marion Hypertension Research Award(1984); American Heart Association Clinician-ScientistAward (1986); Bristol-Myers Squibb UnrestrictedCardiovascular Research Grant Award (1990); AmericanHeart Association Established Investigatorship Award(1992); Robert J. and Claire Pasarow Foundation Award inCardiovascular Research (1992); American HeartAssociation, Edgar Haber Cardiovascular Award (1997);American Heart Association, Helen B. Taussig MemorialLecturer (1997); Member, Johns Hopkins University Societyof Scholars (1998); Member, American Academy of Arts andSciences (1999); Member, Institutes of Medicine (1999);American Heart Association, Basic Research Prize (1999);Gill Heart Institute Award for Cardiovascular Research(2000); American College of Cardiology, Louis F. BishopLecture (2000); Gill Heart Institute Award for CardiovascularResearch (2001); 12th Annual Bristol-Myers Squibb Awardfor Distinguished Achievement in Cardiovascular Research(joint recipient with Jonathan Seidman, PhD) (2002); Fellow,International Society Heart Research (2002); DistinguishedScientist, American Heart Association (2003); CannonAward, American Physiologic Society (2004); Member,Association of University Cardiologists (2005);Distinguished Alumni Achievement Award, The GeorgeWashington University (2005); Member, National Academyof Sciences (2005).

Louis M. Staudt, M.D., Ph.D.Dr. Staudt received his B.A. from Harvard College in 1976and his M.D. and Ph.D. from the University of Pennsylvaniain 1982. His Ph.D. thesis in the laboratory of Walter Gerharddefined somatic hypermutation as a rapid mechanism ofantibody diversification during normal immune responses.Following internal medicine training, he joined DavidBaltimore’s laboratory where he cloned and characterizedthe lymphoid-restricted transcription factor Oct-2. He estab-lished his laboratory in the Metabolism Branch, NCI, in1988, and currently studies the molecular basis of humanlymphoid malignancies.

J. Russell Teagarden, R.Ph., M.A.J. Russell Teagarden currently serves as Vice President ofClinical Practices & Therapeutics at Medco. He joinedMedco in July of 1993 as Director of Clinical Programs.


17

Prior to joining Medco, Mr. Teagarden served for 12 years asa Drug Information Specialist and as a clinical pharmacistspecializing in critical care in the Chicago teaching hospitalcommunity.

Mr. Teagarden currently holds academic appointments atRutgers College of Pharmacy, Ohio Northern UniversityCollege of Pharmacy, and Albany College of Pharmacy. Hewas a visiting scholar in Department of Clinical Bioethics atthe National Institutes of Health from September, 2001 toJune, 2002.

Mr. Teagarden serves as a member of the Board ofTrustees of the Institute for Safe Medication Practices andas a member of the Board of Trustees of the P&T Society.He also serves on the Oversight Body of the AmericanMedical Association Ethical Force Program.

Mr. Teagarden received a Bachelor of Science inPharmacy from the University of Illinois College ofPharmacy, and he completed a residency in hospital phar-macy at Northwestern University Medical Center inChicago. He also holds a Master of Arts degree in ResearchMethodology from Loyola University of Chicago, and is cur-rently a candidate for a Doctorate in Medical Humanities atthe Caspersen School of Graduate Studies of DrewUniversity. He has published several papers on significantmedical, pharmacy, and ethics issues.

Andrew C. von Eschenbach, M.D.Andrew C. von Eschenbach, M.D., is the ActingCommissioner of the U.S. Food and Drug Administration(FDA) and was formerly the 12th Director of the NationalCancer Institute (NCI). A nationally recognized urologic sur-geon and oncologist, Dr. von Eschenbach’s distinguishedcareer as a key leader in the fight against cancer spansnearly three decades.

Prior to being appointed to lead the NCI in January 2002,Dr. von Eschenbach served as Executive Vice President andChief Academic Officer of the University of Texas M.D.Anderson Cancer Center in Houston, leading a faculty ofmore than 1,000 cancer researchers and clinicians. At M.D.Anderson he also served as Vice President for AcademicAffairs and held the Roy M. and Phyllis Gough HuffingtonClinical Research Distinguished Chair in Urologic Oncology.

Dr. von Eschenbach, as founding director of the ProstateCancer Research Program, was instrumental in fosteringintegrated research programs in the biology, epidemiology,prevention, and treatment of prostate cancer at M.D.Anderson where he also directed the Genitourinary CancerCenter. He joined M.D. Anderson as a urologic oncologyfellow in 1976 and was invited to join the faculty the fol-lowing year. Just six years later - in 1983 - he was namedchairman of the Department of Urology. Other positionsheld at M.D. Anderson include Consulting Professor of CellBiology and Professor of Urology.

Dr. von Eschenbach, himself a cancer survivor, has had an

impact on the fight against cancer that extends beyond theclinical and academic communities. He is a founding mem-ber of C-Change and was president-elect of the AmericanCancer Society at the time of his appointment to the NCI.In addition, he has made significant contributions to thescientific literature — more than 200 articles, books, andbook chapters. Dr. von Eschenbach has also served as aneditorial board member of several leading journals and onseveral organizational boards.

Many influential organizations have recognized Dr. vonEschenbach for his leadership and accomplishments; amongthem the American Medical Writers Association, theAmerican Urological Association, and the UniformedServices University of Health Sciences. He also has beenincluded in “The Best Doctors in America” publications.Included among his many honors are the 2003 Carpe DiemAward from the Lance Armstrong Foundation; theAchievement Award from the 100 Black Men ofMetropolitan Houston for his significant contributions toprostate cancer programs in the African-American commu-nity, the Julie Rogers “Spirit of Love” Award for demon-strating unparalleled dedication, commitment, and spirit inthe fight against cancer, and the American Radium SocietyJaneway Medal for outstanding contribution to cancerresearch and the care of cancer patients. In 2006, TimeMagazine chose Dr. von Eschenbach as one of the 100 mostinfluential people to shape the world.

A native of Philadelphia, Dr. von Eschenbach earned aB.S. from St. Joseph’s University in Philadelphia in 1963 andhis medical degree from Georgetown University School ofMedicine in 1967. Dr. von Eschenbach completed intern-ship at Philadelphia General Hospital and residency in uro-logic surgery at Pennsylvania Hospital in Philadelphia andthen was an instructor in urology at the University ofPennsylvania School of Medicine. He also served as aLieutenant Commander in the U.S. Navy Medical Corps.

William J. WelchBill Welch is Senior Vice President and Chief CommercialOfficer with Monogram Biosciences, Inc., where he overseessales, marketing and commercial operations. MonogramBiosciences is a life sciences company committed toadvancing personalized medicine and improving patientoutcomes through the development of molecular diagnosticproducts that guide and target treatments. The Company isdeveloping molecular diagnostics and laboratory services toassist physicians in better managing infectious diseases andcancers, and to enable pharmaceutical companies to devel-op new anti-viral therapeutics and targeted cancer thera-peutics. Monogram is the leading provider of drug suscep-tibility testing for physicians and pharmaceutical companiesin HIV. Monogram’s oncology platform is its eTag technolo-gy, acquired through its merger with ACLARA Biosciences,

continued



18

Inc. (ACLARA) in December 2004.Prior to joining Monogram Biosciences, Bill was an execu-

tive officer and Vice President, Sales & Marketing, with LaJolla Pharmaceutical Company. La Jolla developed specifictherapeutics for antibody-mediated diseases and conductedthe most comprehensive research and largest clinical studiesin patients with lupus, including an NDA filed under SubpartH. Prior to La Jolla, Bill was Vice President of GlobalMarketing for Dade Behring MicroScan where he managedmarketing and strategic development for this global leader inmicrobiology diagnostics. Bill entered the pharmaceuticalindustry with Abbott Laboratories where he held a number ofprogressive positions in management and general manage-ment in therapeutics and medical devices, serving hospitalsand physicians offices.Bill holds a BS in Chemical Engineering from the Universityof California at Berkeley and an MBA from HarvardUniversity.

Catherine Wheeler, M.D.Dr. Catherine Wheeler has worked for AstraZeneca for six

years in medical and team director roles and has mostrecently become Vice President, Strategic Planning andBusiness Development for Oncology and Infection. Shebegan her industry career at Parexel International asExecutive Director for Oncology. Dr. Wheeler trained inhematology and oncology in Boston at Dana-Farber CancerInstitute and Beth Israel Hospital, and for many year wasDirector of the autologous bone marrow transplant programat Beth Israel Hospital.

Tony L. WhiteTony L. White became Chairman of the Board, President andChief Executive Officer of the company in 1995. He alsochairs the company’s Executive Committee. Mr. White refo-cused the company purely on life sciences and transformed itinto the leading provider of tools and information resourcesfor that market. Mr. White led the recapitalization of thecompany in 1999, after which the company launched twoseparately traded common stocks, and also directed theeffort to complete the sale of the company’s analyticalinstruments division. Applera Corporation’s AppliedBiosystems group serves the life sciences industry andresearch community by developing and marketing instru-ment-based systems, consumables, software, and services.Applied Biosystems’ products also serve the needs of somemarkets outside of life science research, which Applera refersto as “applied markets,” such as the fields of: human identitytesting, biosecurity, and quality and safety testing. Its CeleraGenomics Group, which Mr. White was instrumental in creat-ing in 1998, is primarily a molecular diagnostics businessthat is using proprietary genomics and proteomics discoveryplatforms to identify and validate novel diagnostic markers,

and is developing diagnostic products based on these mark-ers as well as other known markers. Celera Genomics main-tains a strategic alliance with Abbott for the developmentand commercialization of molecular, or nucleic acid-based,diagnostic products, and it is also developing new diagnosticproducts outside of this alliance. Through its genomics andproteomics research efforts, Celera Genomics is also discov-ering and validating therapeutic targets, and it is seekingstrategic partnerships to develop therapeutic products basedon these discovered targets.

Mr. White graduated from Western Carolina University andheld a number of management positions both in U.S. andinternational locations during a 26-year career at BaxterInternational, Inc. He served as Executive Vice President andwas a member of the Office of the Chief Executive at Baxterprior to joining the company. He continues to serve on theBoards of Directors of C.R. Bard, Inc. and Ingersoll-RandCompany Ltd.

Ron WinslowRon Winslow is deputy editor, health and science and a sen-ior medical and health care writer for the Wall Street Journal.In the past 17 years, he has written more than 1,100 articlesdescribing new medical and health care research and chroni-cling the forces of economics and innovation that are trans-forming the U.S health care system. He also helps edit andoversee the paper’s health and medical coverage. In 2003,Mr. Winslow received the American Heart Association’sHoward L. Lewis Award for his coverage of cardiovasculardisease for “consumers, practitioners, policymakers and busi-ness people.” His work has also been honored by theNational Alliance for the Mentally Ill and other groups. He isa member of the National Association of Science Writers andwas a founding board member of the Association of HealthCare Journalists.

Michael A. Zoccoli, Ph.D.Mike Zoccoli is Vice President of Development, InstrumentSystems and Software for Celera, where he is responsible fordevelopment of new diagnostic assays and products, and forthe management of the Design Control Process. He earned aBA in Chemistry in 1973 at the University of Connecticut anda Ph.D. in Chemistry in 1978 from Dartmouth College. Afterpost-doctoral studies at Harvard Medical School supportedby fellowships from the National Institutes of Health and theJuvenile Diabetes Foundation, he started his career in thediagnostics industry at Syva Company in 1982. He hasworked for the past 24 years in positions of increasingresponsibility in product development and project manage-ment in a number of companies including Cetus, RocheMolecular Systems, Applied Imaging Corporation, and BayerDiagnostics.


19

The past several years have fueled a revolution in human genetics, which is having avery significant impact on virtually all specialties of medicine. There are several scientificadvances that are responsible for this revolution. One is the recognition that the geneticcomposition of humans has a significant role to play in that individual’s health and pre-disposition to common diseases such as heart disease and cancer. The second is the avail-ability of the human genome sequence and the many high throughput technologies thathave been developed during the human genome project. This new genomic era providesexcellent opportunities to identify genes and the specific genetic changes that are respon-sible for human disease, and to understand how such changes cause disease. In the clini-cal arena, it is becoming possible to utilize the emerging genetic and genomic knowledgeto diagnose and treat patients. Widespread use of such genetic and genomic informationwill revolutionize medical practice. In the area of treatment, the knowledge of the genet-ic basis of human disease is ushering a new era in drug development that is focused ontargeted drug development. Genetic profiling of individuals in clinical trials will help incorrelating individuals with their response to specific drugs, leading to the era of person-alized medicine.

To realize the promise of genetics and genomics in research and in medical practice, theHarvard Medical School-Partners Healthcare Center for Genetics and Genomics(HPCGG) was established in the fall of 2001. Its mission is to accelerate the realizationof personalized medicine by discovering and integrating genetic knowledge into thehealthcare system. Raju Kucherlapati, Ph.D., the Paul C. Cabot Professor of Genetics atHarvard Medical School, is the Center’s first scientific director.

The mission of the Center is being accomplished through the following approaches:

• Recruiting outstanding faculty• Providing enabling technologies for researchers• Offering genetic-based diagnostic testing• Caring for patients with genetic disorders• Training and educating physicians, scientists and the public• Developing an IT infrastructure to integrate genetic and genomic

data into clinical decision support systems

For more information about the Center please visit www.hpcgg.org or write to us at:

77 Avenue Louis PasteurNRB Suite 250

Boston, MA 02115

[email protected]

Personalized Medicine:

A World of Opportunities77 Avenue Louis Pasteur

NRB Suite 250Boston, MA 02115

[email protected]

personalized medicine...personalized medicine: a world of opportunities a conference hosted by...

Documents